[
  {
    "ts": "2026-02-05T00:00:00+00:00",
    "headline": "Amazon earnings, Fed commentary, mortgage rates: What to Watch",
    "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, February 5, including earnings results from companies like Amazon (AMZN), Strategy (MSTR), Shell (SHEL), and ConocoPhillips (COP); commentary from Federal Reserve Bank of Atlanta President Raphael Bostic; and the latest reading on US mortgage rates. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Domination Overtime.",
    "url": "https://finance.yahoo.com/video/amazon-earnings-fed-commentary-mortgage-000000507.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "6c52d518-186f-3679-b4b3-950c7dd2109e",
      "content": {
        "id": "6c52d518-186f-3679-b4b3-950c7dd2109e",
        "contentType": "VIDEO",
        "title": "Amazon earnings, Fed commentary, mortgage rates: What to Watch",
        "description": "<p>Market Domination Overtime Host <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/josh-lipton/\">Josh Lipton</a> previews several of the biggest stories to come tomorrow, Thursday, February 5, including earnings results from companies like Amazon (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/AMZN\">AMZN</a>), Strategy (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/MSTR\">MSTR</a>), Shell (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/SHEL\">SHEL</a>), and ConocoPhillips (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/COP\">COP</a>); commentary from Federal Reserve Bank of Atlanta President Raphael Bostic; and the latest reading on US mortgage rates.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-domination-overtime/\">Market Domination Overtime</a>.</p>",
        "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, February 5, including earnings results from companies like Amazon (AMZN), Strategy (MSTR), Shell (SHEL), and ConocoPhillips (COP); commentary from Federal Reserve Bank of Atlanta President Raphael Bostic; and the latest reading on US mortgage rates. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Domination Overtime.",
        "pubDate": "2026-02-05T00:00:00Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/20ccb290-01f4-11f1-ac7f-afc2136f88e9",
          "originalWidth": 4096,
          "originalHeight": 2304,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/64AWZpDFkVsz1KJ_zzIGkg--~B/aD0yMzA0O3c9NDA5NjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/20ccb290-01f4-11f1-ac7f-afc2136f88e9.cf.webp",
              "width": 4096,
              "height": 2304,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lG_SMEjPLlKpXjfQdHMGRQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/20ccb290-01f4-11f1-ac7f-afc2136f88e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/amazon-earnings-fed-commentary-mortgage-000000507.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/amazon-earnings-fed-commentary-mortgage-000000507.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "COP"
            },
            {
              "symbol": "RYDAF"
            },
            {
              "symbol": "SHEL"
            },
            {
              "symbol": "CI"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "STRC"
            },
            {
              "symbol": "STRD"
            },
            {
              "symbol": "STRF"
            },
            {
              "symbol": "STRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T13:00:00+00:00",
    "headline": "Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals",
    "summary": "This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends. It has been compiled by Towards Healthcare, a sister firm of Precedence Research, offering valuable insights into the latest developments and financials in this rapidly advancing field.Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb",
    "url": "https://finance.yahoo.com/news/cell-gene-therapy-numbers-1-130000843.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "d5984552-e132-3083-92f2-3c08de3750a2",
      "content": {
        "id": "d5984552-e132-3083-92f2-3c08de3750a2",
        "contentType": "STORY",
        "title": "Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals",
        "description": "",
        "summary": "This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends. It has been compiled by Towards Healthcare, a sister firm of Precedence Research, offering valuable insights into the latest developments and financials in this rapidly advancing field.Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb",
        "pubDate": "2026-02-05T13:00:00Z",
        "displayTime": "2026-02-05T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7",
          "originalWidth": 1667,
          "originalHeight": 1667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2XVm_GDF06LCL8xJEgs9kg--~B/aD0xNjY3O3c9MTY2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7.cf.webp",
              "width": 1667,
              "height": 1667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ciHBcKYhN1HkkZYm0oIo1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cell-gene-therapy-numbers-1-130000843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cell-gene-therapy-numbers-1-130000843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T12:30:21+00:00",
    "headline": "Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off",
    "summary": "By Michael Erman Feb 5 (Reuters) - Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue,",
    "url": "https://finance.yahoo.com/news/bristol-myers-forecasts-upbeat-2026-122544598.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "cd30cc79-b136-3169-b28a-29a75faca051",
      "content": {
        "id": "cd30cc79-b136-3169-b28a-29a75faca051",
        "contentType": "STORY",
        "title": "Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off",
        "description": "",
        "summary": "By Michael Erman Feb 5 (Reuters) - Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue,",
        "pubDate": "2026-02-05T12:30:21Z",
        "displayTime": "2026-02-05T12:30:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/f13d33d6bebf64c8094fff8ae80a91ce",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021.    REUTERS/Brian Snyder",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m_xlhmzHhY1aSUGjS1qOIA--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/f13d33d6bebf64c8094fff8ae80a91ce.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TgKEzg9BCh89gV8EeJTIJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/f13d33d6bebf64c8094fff8ae80a91ce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-forecasts-upbeat-2026-122544598.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-forecasts-upbeat-2026-122544598.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T12:09:07+00:00",
    "headline": "Bristol Myers: Q4 Earnings Snapshot",
    "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported fourth-quarter net income of $1.09 billion. The Princeton, New Jersey-based company said it had profit of 53 cents per share. Earnings, adjusted for non-recurring costs, came to $1.26 per share.",
    "url": "https://finance.yahoo.com/news/bristol-myers-q4-earnings-snapshot-120907492.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "9791912b-8e8f-33a8-9c79-b70e7078f235",
      "content": {
        "id": "9791912b-8e8f-33a8-9c79-b70e7078f235",
        "contentType": "STORY",
        "title": "Bristol Myers: Q4 Earnings Snapshot",
        "description": "",
        "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported fourth-quarter net income of $1.09 billion. The Princeton, New Jersey-based company said it had profit of 53 cents per share. Earnings, adjusted for non-recurring costs, came to $1.26 per share.",
        "pubDate": "2026-02-05T12:09:07Z",
        "displayTime": "2026-02-05T12:09:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-q4-earnings-snapshot-120907492.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-q4-earnings-snapshot-120907492.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T12:09:00+00:00",
    "headline": "Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth",
    "summary": "Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs.",
    "url": "https://www.wsj.com/business/earnings/bristol-myers-squibb-revenue-ticks-up-on-immuno-oncology-growth-8c4bf745?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "15c339cc-1a27-3943-bb09-775568a510fe",
      "content": {
        "id": "15c339cc-1a27-3943-bb09-775568a510fe",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth",
        "description": "",
        "summary": "Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs.",
        "pubDate": "2026-02-05T12:09:00Z",
        "displayTime": "2026-02-05T12:09:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/15c339cc-1a27-3943-bb09-775568a510fe/bristol-myers-squibb-revenue.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/4ab676f7197f892fe88978c84a4ce696",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nIyi47pfBjsNePKZZ85l9Q--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/4ab676f7197f892fe88978c84a4ce696.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KWem.mH2GvOoeMyi2q6Q7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/4ab676f7197f892fe88978c84a4ce696.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/earnings/bristol-myers-squibb-revenue-ticks-up-on-immuno-oncology-growth-8c4bf745?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-05T11:59:00+00:00",
    "headline": "Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025",
    "summary": "PRINCETON, N.J., February 05, 2026--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-reports-fourth-115900357.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "15b7b6ba-21d8-37bf-a88d-3c1503ff2aff",
      "content": {
        "id": "15b7b6ba-21d8-37bf-a88d-3c1503ff2aff",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025",
        "description": "",
        "summary": "PRINCETON, N.J., February 05, 2026--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025",
        "pubDate": "2026-02-05T11:59:00Z",
        "displayTime": "2026-02-05T11:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/cae83d4626ebdedb8a7927edc5145b6e",
          "originalWidth": 1497,
          "originalHeight": 206,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9YmTtgw542cHs6.xMlKOrg--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cae83d4626ebdedb8a7927edc5145b6e.cf.webp",
              "width": 1497,
              "height": 206,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l__HnsNMm5JRyDXXzouxeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cae83d4626ebdedb8a7927edc5145b6e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-reports-fourth-115900357.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-reports-fourth-115900357.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]